(Q36598119)

15 August 2017

1 reference

title

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics (English)

1 reference

15 August 2017

0 references

0 references

Sheila M Wilhelm

1

1 reference

15 August 2017

Jason D Taylor

series ordinal

2

1 reference

15 August 2017

Lisa L Osiecki

series ordinal

3

1 reference

15 August 2017

Pramodini B Kale-Pradhan

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

19 September 2006

1 reference

Annals of Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

40

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

1804-1813

1 reference

Medical options for treating Crohn's disease in adults: focus on antitumor necrosis factor-alpha chimeric monoclonal antibody

15 August 2017

cites work

1 reference

Management of Crohn's disease in adults

21 January 2018

1 reference

Cytokines in inflammatory bowel disease

21 January 2018

1 reference

New concepts in the pathophysiology of inflammatory bowel disease

21 January 2018

1 reference

Mucosal flora in inflammatory bowel disease

21 January 2018

1 reference

Antibiotics for inflammatory bowel disease: do they work?

21 January 2018

1 reference

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

21 January 2018

1 reference

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

Recent developments in the pharmacological treatment of Crohn's disease

21 January 2018

1 reference

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

21 January 2018

1 reference

Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine

21 January 2018

1 reference

6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment

21 January 2018

1 reference

6-thioguanine--efficacy and safety in chronic active Crohn's disease

21 January 2018

1 reference

Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease

21 January 2018

1 reference

Long-term tacrolimus: a promising therapeutic approach for Crohn's disease

21 January 2018

1 reference

Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study

21 January 2018

1 reference

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy

21 January 2018

1 reference

Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis

21 January 2018

1 reference

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

An open-label evaluation of rifaximin in the treatment of active Crohn's disease

21 January 2018

1 reference

Preliminary study of ciprofloxacin in active Crohn's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H038

1 reference

15 August 2017

1 reference